Novartis Delighted With Xiidra Deal Despite Eye-Watering Price
Executive Summary
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
You may also be interested in...
Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb
The Swiss drug maker said it would sell the underperforming dry eye drug plus pipeline assets and rights to a delivery device for $2.5bn, which for Bausch + Lomb means a bigger presence in the space.
The Eyes Still Have It For Novartis Despite Sell-Off Rumors
Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.
Oyster Point Prepares Major Push For New Dry Eye Drug
Execs told Scrip they hope to get Tyrvaya (varenicline) onto formularies and aim for pricing that would make its nasal spray competitive with Restasis and Xiidra.